Immune combinational therapy targeting OX40 and IDO synergistically enhances efficacy of a cancer vaccine by unknown
POSTER PRESENTATION Open Access
Immune combinational therapy targeting OX40
and IDO synergistically enhances efficacy of a
cancer vaccine
Zuzana Berrong1, Shamim Ahmad1, Rasha Abu Eid1, Abdeljabar El Andaloussi1, Tanusree Sen1, Ross Stewart2,
Scott A Hammond3, Rajeev Shrimali1, Mikayel Mkrtichyan1*, Samir N Khleif1
From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014
Enhancing an effector immune response by cancer vac-
cines has not been clinically successful so far. Although
the necessary immune response may be elicited using
vaccine-based therapies, this has not been sufficient for a
positive clinical outcome; since most cancers can escape
immune surveillance via multiple immune suppressive
mechanisms induced in the tumor environment. A rela-
tively recent strategy to increase the therapeutic efficacy of
tumor vaccination is to combine it with alternative immu-
notherapeutic approaches.
Here we tested if simultaneous targeting of the effec-
tor arm of the immune system with an agonist anti-
OX40 mAb together with targeting of suppressive
mechanisms in the tumor, via inhibition of indoleamine-
(2,3)-dioxygenase (IDO), could enhance the anti-tumor
activity of vaccine in mouse models of cancer.
The OX40 molecule is a co-stimulatory receptor
expressed on T-cells that can lead to proliferation and
enhancement of T-cell effector function when triggered
with an agonistic antibody. However, the tumor secretes a
number of suppressive signals as a protective mechanism
against its destruction, one of which is IDO. We demon-
strate that treatment of TC-1 tumor bearing mice with an
anti-OX40 agonist antibody in combination with vaccine
leads to the enhancement of antigen-specific T cell
responses. The dose of 1 mg/kg anti-OX40 antibody
stimulated the effector arm of T cells, which ultimately led
to a significant increase in the CD8+/regulatory T-cell
(Treg) ratio within tumors. Further, this combination
of vaccine and anti-OX40 antibody treatment led to a sig-
nificant inhibition of tumor growth and to a prolonged
survival of tumor bearing mice compared to control, and
resulted in complete tumor regression in 20% of treated
mice. We found, however, that this anti-tumor activity
could be further enhanced through the combination of
vaccine, anti-OX40 and 1-methyltryptophan (1-MT), an
IDO activity inhibitor. IDO has been shown to be secreted
by tumor cells, suppressive dendritic cells and macro-
phages in tumor environment, and is known to be respon-
sible for suppressing effector cells and inducing Tregs.
Our data demonstrate that vaccine/anti-OX40 antibody/
1-MT combination leads to a more profound inhibition of
tumor growth in mice and complete regression of estab-
lished tumors in 60% of treated mice. In conclusion, we
provide evidence that simultaneous targeting of the effec-
tor arm of the immune system, via anti-OX40 antibody,
and suppressive mechanisms within the tumor, via 1-MT,
in combination with cancer vaccine has a synergistic effect
for tumor eradication and is a promising strategy that
could potentially enhance the overall efficacy of cancer
treatment in patients.
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